- AU$47.28m
- AU$50.53m
- AU$14.12m
- 37
- 54
- 61
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16.52 | ||
| PEG Ratio (f) | 0.21 | ||
| EPS Growth (f) | 338.74% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.77 | ||
| Price to Tang. Book | 1.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -19.25% | ||
| Return on Equity | -19.31% | ||
| Operating Margin | -27.35% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 14.17 | 16.93 | 12.13 | 7.03 | 14.12 | 24.3 | 27.4 | 3.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +40 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IDT Australia Limited is a pharmaceutical manufacturing company. The Company is engaged in the supply of products and provision of research and development and other technical services within the pharmaceutical and allied industries. Its business includes research and development, active pharmaceutical ingredient (API) and finished dosage form manufacture (FDF), clinical and commercial, project management, chemical services, analytical chemistry, pharmacy services, pharmaceutical development in all dosage forms, clinical packaging and regulatory affairs services. Its Current Good Manufacturing Practice (cGMP) manufacturing facilities produces both API and FDF across the medicinal cannabis manufacturing space. It also provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms. Its analytical laboratories offer medicinal cannabis cGMP testing.
Directors
- Alan Fisher CHM
- David Sparling CEO
- Ancila Desai CFO
- Jane Kelly VPR
- Hugh Burrill DRC (54)
- Michael Kotsanis NID
- Jane Ryan NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 11th, 1986
- Public Since
- March 22nd, 1988
- No. of Shareholders
- 3,444
- No. of Employees
- 156
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 429,841,870
- Address
- 45 Wadhurst Dr, Boronia, MELBOURNE, 3155
- Web
- https://en.idtaus.com.au/
- Phone
- +61 null398018888
- Auditors
- RSM Australia Partners
Upcoming Events for IDT
Similar to IDT
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the IDT Australia share price?
As of Today at 21:13 UTC, shares in IDT Australia are trading at AU$0.11. This share price information is delayed by 15 minutes.
How has the IDT Australia share price performed this year?
Shares in IDT Australia last closed at AU$0.11 and the price had moved by +15.79% over the past 365 days. In terms of relative price strength the IDT Australia share price has outperformed the ASX All Ordinaries Index by +11.59% over the past year.
What are the analyst and broker recommendations for IDT Australia?
There is no consensus recommendation for this security.
Find out moreWhat is the IDT Australia dividend yield?
IDT Australia does not currently pay a dividend.
Does IDT Australia pay a dividend?
IDT Australia does not currently pay a dividend.
When does IDT Australia next pay dividends?
IDT Australia does not currently pay a dividend.
How do I buy IDT Australia shares?
To buy shares in IDT Australia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IDT Australia?
As of the previous close price of AU$0.11, shares in IDT Australia had a market capitalisation of AU$47.28m.
Where are IDT Australia shares listed?
Here are the trading details for IDT Australia:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IDT
What kind of share is IDT Australia?
Based on an overall assessment of its quality, value and momentum IDT Australia is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IDT Australia share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the IDT Australia share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IDT Australia. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -11.25%.
As of the last closing price of AU$0.11, shares in IDT Australia were trading -1.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IDT Australia PE Ratio?
The IDT Australia PE ratio based on its reported earnings over the past 12 months is 16.52. The shares last closed at AU$0.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IDT Australia?
IDT Australia's management team is headed by:
- Alan Fisher - CHM
- David Sparling - CEO
- Ancila Desai - CFO
- Jane Kelly - VPR
- Hugh Burrill - DRC
- Michael Kotsanis - NID
- Jane Ryan - NID